InVivoMAb anti-human PD-L1 (B7-H1)

Sivakumar R, Chan M, Shin JS, et al. Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery. Oncoimmunology. 2019,8(12):e1670019. doi: 10.1080/2162402X.2019.1670019

Broos K, Lecocq Q, Keersmaecker B, et al. Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production. Vaccines (Basel). 2019,7(3). doi: 10.3390/vaccines7030085

Porichis F, Hart MG, Zupkosky J, et al. Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions. J Virol. 2014,88(5):2508-18. doi: 10.1128/JVI.02034-13

Hegde S, Lockridge JL, Becker YA, et al. Human NKT cells direct the differentiation of myeloid APCs that regulate T cell responses via expression of programmed cell death ligands. J Autoimmun. 2011,37(1):28-38. doi: 10.1016/j.jaut.2011.03.001

Nakamoto N, Cho H, Shaked A, et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 2009,5(2):e1000313. doi: 10.1371/journal.ppat.1000313

Cai G, Karni A, Oliveira EM, et al. PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol. 2004,230(2):89-98.

Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003,170(3):1257-66.